Correlation Between Viracta Therapeutics and Supernus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Viracta Therapeutics and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Supernus Pharmaceuticals.

Diversification Opportunities for Viracta Therapeutics and Supernus Pharmaceuticals

-0.63

Correlation Coefficient

Viracta Therapeutics  Supernus Pharmaceuticals

Excellent diversification

The 3 months correlation between Viracta and Supernus is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Supernus Pharmaceuticals

Given the investment horizon of 90 days Viracta Therapeutics is expected to generate 40.32 times less return on investment than Supernus Pharmaceuticals. In addition to that, Viracta Therapeutics is 4.25 times more volatile than Supernus Pharmaceuticals. It trades about 0.0 of its total potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about 0.12 per unit of volatility. If you would invest  3,292  in Supernus Pharmaceuticals on October 14, 2024 and sell it today you would earn a total of  457.00  from holding Supernus Pharmaceuticals or generate 13.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Viracta Therapeutics  vs.  Supernus Pharmaceuticals

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Viracta Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Supernus Pharmaceuticals

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Viracta Therapeutics and Supernus Pharmaceuticals

The main advantage of trading using opposite Viracta Therapeutics and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.

The idea behind Viracta Therapeutics and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.